908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
908 Devices Inc. President and CEO Kevin J. Knopp reported an open-market sale of 2,798 shares of common stock at a weighted average price of $9.09 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 20, 2025.
Following the sale, Knopp directly holds 732,825 shares of common stock. In addition, 541,223 shares are held indirectly by The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother-in-law serves as trustee and has sole voting and dispositive control; Knopp may be deemed the beneficial owner of those securities.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of 9,900 shares of common stock at a weighted average price of $9.04 per share. The trades were executed at prices ranging from $9.00 to $9.08.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. After the sale, Brown directly holds 865,559 shares of 908 Devices common stock, indicating he retains a substantial equity position in the company.
908 Devices Inc. President and CEO Kevin J. Knopp reported open‑market sales of 60,345 shares of common stock over three days at prices around $9.06–$9.14 per share. These transactions were made pursuant to a Rule 10b5‑1 trading plan adopted on May 20, 2025, indicating they were pre‑scheduled.
After these sales, Knopp directly holds 735,623 shares of 908 Devices common stock. In addition, 541,223 shares are held indirectly through The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother‑in‑law serves as trustee with sole voting and dispositive power, and of which Knopp may be deemed the beneficial owner.
908 Devices Inc. director Michele M. Leonhart exercised restricted stock units into common shares as part of equity compensation. She acquired 6,486 shares of common stock through the conversion of 6,486 restricted stock units at a stated price of $0.00 per share.
Following the transaction, Leonhart directly holds 27,054 shares of common stock. The restricted stock units underlying this exercise vest in substantially equal annual installments over three years starting June 25, 2024, with prorated vesting if service ends earlier, and represent the right to receive one share of common stock per unit when vested.
AWM Investment Company, Inc., a greater-than-10% owner of 908 Devices Inc., reported open-market sales of the company’s common stock through limited partnerships it advises. On June 22 and 23, the funds sold a total of 7,718 shares at prices around $9 per share. After these trades, entities advised by AWM indirectly held 4,879,773 shares of common stock, spread across several Special Situations funds. AWM is described as having sole voting and investment power over these fund holdings, while formally disclaiming beneficial ownership except to the extent of its pecuniary interest.
908 Devices Inc. director Brandi C. Vann received new equity awards consisting of stock options and restricted stock units. The filing shows a grant of options to buy 6,209 shares of Common Stock at an exercise price of $8.22 per share, expiring on June 10, 2036. These options vest in substantially equal monthly installments over the 12 months following June 11, 2026, contingent on continued service.
Vann also received 13,656 Restricted Stock Units, each representing a contingent right to one share of Common Stock. The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of Stockholders, whichever occurs first, with prorated vesting if service ends earlier. These are compensation-related awards rather than open-market purchases or sales.
908 Devices Inc. director Michele M. Leonhart reported equity compensation transactions involving stock options, restricted stock units (RSUs), and common shares. On June 10, 2026, 14,083 RSUs fully vested and were converted into 14,083 shares of common stock, increasing her direct common stock holdings to 20,568 shares.
On June 11, 2026, she received a grant of 6,209 stock options with an exercise price of $8.22 per share that vest in substantially equal monthly installments over 12 months. She also received 13,656 RSUs that vest in full on June 11, 2027 or the day prior to the 2027 annual stockholders meeting, subject to continued service, with prorated vesting if service ends earlier.
908 Devices Inc. director E. Kevin Hrusovsky reported several equity compensation awards and related share movements. He received a stock option grant for 6,209 shares of Common Stock at an exercise price of $8.22 per share, vesting in substantially equal monthly installments over 12 months following June 11, 2026, and expiring on June 10, 2036.
He was also granted 13,656 Restricted Stock Units (RSUs), each representing one share of Common Stock, which become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of Stockholders, subject to continued service and prorated vesting on earlier termination. In addition, 14,083 RSUs became fully vested on June 10, 2026 and were converted into 14,083 shares of Common Stock, bringing his direct Common Stock holdings to 165,390 shares. A further 329,675 shares of Common Stock are held indirectly through the E. Kevin Hrusovsky 2012 Irrevocable Trust, for which his spouse and children serve as trustees and over which he may be deemed a beneficial owner.
908 Devices Inc. director Anthony Hunt reported routine equity compensation and a vesting event. He received a stock option for 6,209 shares of Common Stock with an exercise price of $8.22 per share, vesting in substantially equal monthly installments over the 12 months following June 11, 2026, and expiring on June 10, 2036. He was also granted 13,656 Restricted Stock Units (RSUs), which will fully vest on June 11, 2027 or the day prior to the 2027 Annual Meeting of Stockholders, subject to continued service, with prorated vesting upon earlier termination. Separately, 14,083 RSUs became fully vested on June 10, 2026 and were converted into 14,083 shares of Common Stock, increasing his direct Common Stock holdings to 44,168 shares.